Brainomix is one of the most commercially advanced AI neuroimaging companies in stroke, with eight FDA clearances, Series C+ funding, and a secondary lung-imaging platform developed in partnership with Boehringer Ingelheim. Its dual-platform strategy across stroke and pulmonary fibrosis is atypical for neurotech companies and diversifies its revenue base, though it also dilutes its positioning as a pure neurotechnology play.